Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon BIEMANS, Nathalie Marie-Josephe GARCON, Philippe Vincent HERMAND, Jan POOLMAN, Marcelle Paulette VAN MECHELEN
Life of this patent
Estimating the term…
Abstract
The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
Claims13
An immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid comprising pneumolysin detoxified by chemical means or diphtheria toxoid or CRM197 and 19F is conjugated to a second bacterial toxoid comprising diphtheria toxoid or CRM197 and further comprising conjugates of S. pneumoniae capsular saccharides 1, 4, 5, 6B, 7F, 9V, 14, 18C, 22F and 23F.
An immunogenic composition comprising at least four S. pneumoniae capsular saccharide conjugates containing saccharides from different S. pneumoniae serotypes wherein at least one saccharide is conjugated to PhtD or fusion protein thereof and the immunogenic composition is capable of eliciting an effective immune response against PhtD.
Dependencies are inferred from the claim text.